PTC Therapeutics has announced three Canadian sites for their clinical trial known as Study 041 for Duchenne muscular dystrophy. Study 041 is looking at how the investigational treatment, ataluren, affects ability to walk and endurance in males aged five years and older with nmDMD, compared to placebo.
More information about the study can be found by clicking here or by visiting clinicaltrials.gov.
For more information about enrolment, contact your doctor or the trial investigator directly. You can also contact PTC at email@example.com
Canadian sites for Study 041:
British Columbia Childrens Hospital
Vancouver, British Columbia, Canada, V6H 3V4 Contact: Mihaela Anghelina 604-875-2345 ext 7132 Mihaela.Anghelina@cw.bc.ca
Principal Investigator: Kathryn Selby, MD
Children’s Hospital London Health Sciences Centre
London, Ontario, Canada, N6A5W9
Contact: Jennifer Petzke 519-685-8500 ext 56109 firstname.lastname@example.org
Principal Investigator: Craig Campbell, MD
Childrens Hospital of Eastern Ontario
Ottawa, Ontario, Canada, K1H8L1
Contact: Rosa Ramos Garcia 613-737-7600 ext 6058 email@example.com
Principal Investigator: Hugh McMillan, MD